Cell- and biomarker-based assays for predicting nephrotoxicity

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 12, 2014, Pages 1621-1635

  Huang, Johnny X ^a   Blaskovich, Mark A ^a   Cooper, Matthew A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Adverse drug reaction; Biomarker; Cell based assay; Drug discovery; Kidney; Nephrotoxicity; Renal failure; Screening; Three dimensional culture

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CLUSTERIN; CYSTATIN C; CYTOKINE; MEMBRANE PROTEIN; MICRORNA; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN KIM 1; PROTEIN TFF3; UNCLASSIFIED DRUG;

ASSAY; CELL TYPE; CULTURE TECHNIQUE; EARLY DIAGNOSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CELL CULTURE; KIDNEY INJURY; KIDNEY ON A CHIP; LABORATORY DEVICE; METABOLITE; NEPHROTOXICITY; NONHUMAN; REVIEW; TECHNOLOGY; ACUTE KIDNEY FAILURE; ANIMAL; BIOASSAY; CELL CULTURE; CHEMICALLY INDUCED; DRUG EFFECTS; HIGH THROUGHPUT SCREENING; KIDNEY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; REPRODUCIBILITY; RISK ASSESSMENT; TOXICITY TESTING;

ACUTE KIDNEY INJURY; ANIMALS; BIOLOGICAL ASSAY; BIOMARKERS; CELL CULTURE TECHNIQUES; CELLS, CULTURED; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; KIDNEY; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; TOXICITY TESTS;

EID: 84911457342     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.967681     Document Type: Review

References (139)

1. Choudhury D, Ahmed Z. Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol 2006;2(2):80-91
2. Rewa O, Bagshaw SM. Acute kidney injury-epidemiology, outcomes and economics. Nat Rev Nephrol 2014;10(4):193-207
3. Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 2013;17(1):204
4. Hsu RK, McCulloch CE, Dudley RA, et al. Temporal changes in incidence of dialysis-requiring AKI. J Am Soc Nephrol 2013;24(1):37-42
5. Campion S, Aubrecht J, Boekelheide K, et al. The current status of biomarkers for predicting toxicity. Expert Opin Drug Metab Toxicol 2013;9(11):1391-408
6. Bucaloiu ID, Kirchner HL, Norfolk ER, et al. Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury. Kidney Int 2012;81(5):477-85
7. Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 2008;48:463-93
8. Cook D, Brown D, Alexander R, et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a fivedimensional framework. Nat Rev Drug Discov 2014;13(6):419-31
9. Loghman-Adham DM, Kiu Weber DCI, Ciorciaro DC, et al. Detection and management of nephrotoxicity during drug development. Expert Opin Drug Saf 2012;11(4):581-96
10. Swan SK. The search continues-an ideal marker of GFR. Clin Chem 1997;43(6 Pt 1):913-14
11. Bonventre JV, Vaidya VS, Schmouder R, et al. Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol 2010;28(5):436-40
12. Fuchs TC, Hewitt P. Biomarkers for drug-induced renal damage and nephrotoxicity-an overview for applied toxicology. The AAPS J 2011;13(4):615-31
13. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006;354(23):2473-83
14. Muller PY, Dieterle F. Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring. Expert Opin Drug Metab Toxicol 2009;5(9):1023-38
15. Zandi-Nejad K, Eddy AA, Glassock RJ, Brenner BM. Why is proteinuria an ominous biomarker of progressive kidney disease?. Kidney Int Suppl 2004(92):S76-89
16. McCullough PA, Bouchard J, Waikar SS, et al. Implementation of novel biomarkers in the diagnosis, prognosis, and management of acute kidney Injury: executive summary from the tenth consensus conference of the acute dialysis quality initiative (ADQI). Contrib Nephrol 2013;182:5-12
17. Edelstein CL. Biomarkers in kidney disease. Academic Press/Elsevier; London: 2010
18. Fassett RG, Venuthurupalli SK, Gobe GC, et al. Biomarkers in chronic kidney disease: a review. Kidney Int 2011;80(8):806-21
19. Sistare FD, Dieterle F, Troth S, et al. Towards consensus practices to qualify safety biomarkers for use in early drug development. Nat Biotechnol 2010;28(5):446-54
20. Dieterle F, Sistare F, Goodsaid F, et al. Renal biomarker qualification submission: a dialog between the FDAEMEA and Predictive Safety Testing Consortium. Nat Biotechnol 2010;28(5):455-62
21. Silberstein E, Konduru K, Kaplan GG. The interaction of hepatitis A virus (HAV) with soluble forms of its cellular receptor 1 (HAVCR1) share the physiological requirements of infectivity in cell culture. Virol J 2009;6:175
22. Tami C, Silberstein E, Manangeeswaran M, et al. Immunoglobulin A (IgA) is a natural ligand of hepatitis A virus cellular receptor 1 (HAVCR1), and the association of IgA with HAVCR1 enhances virus-receptor interactions. J Virol 2007;81(7):3437-46
23. Bailly V, Zhang Z, Meier W, et al. Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. J Biol Chem 2002;277(42):39739-48
24. Vaidya VS, Ramirez V, Ichimura T, et al. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 2006;290(2):F517-29
25. Han WK, Bailly V, Abichandani R, et al. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002;62(1):237-44
26. Ozer JS, Dieterle F, Troth S, et al. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat Biotechnol 2010;28(5):486-94
27. Vaidya VS, Ozer JS, Dieterle F, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol 2010;28(5):478-85
28. Zhou Y, Vaidya VS, Brown RP, et al. Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. Toxicol Sci 2008;101(1):159-70
29. van Timmeren MM, van den Heuvel MC, Bailly V, et al. Tubular kidney injury molecule-1 (KIM- 1) in human renal disease. J Pathol 2007;212(2):209-17
30. Han WK, Waikar SS, Johnson A, et al. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int 2008;73(7):863-9
31. Madero M, Sarnak MJ, Stevens LA. Serum cystatin C as a marker of glomerular filtration rate. Curr Opin Nephrol Hypertens 2006;15(6):610-16
32. Dieterle F, Perentes E, Cordier A, et al. Urinary clusterin, cystatin C, beta2- microglobulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol 2010;28(5):463-9
33. Shlipak MG, Matsushita K, Arnlov J, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 2013;369(10):932-43
34. Jones SE, Jomary C. Clusterin. Int J Biochem Cell Biol 2002;34(5):427-31
35. Hoffmann D, Fuchs TC, Henzler T, et al. Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity. Toxicology 2010;277(1-3):49-58
36. Rosenberg ME, Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995;27(7):633-45
37. Ishii A, Sakai Y, Nakamura A. Molecular pathological evaluation of clusterin in a rat model of unilateral ureteral obstruction as a possible biomarker of nephrotoxicity. Toxicol Pathol 2007;35(3):376-82
38. Madsen J, Nielsen O, Tornoe I, et al. Tissue localization of human trefoil factors 1, 2, and 3. J Histochem Cytochem 2007;55(5):505-13
39. Yu Y, Jin H, Holder D, et al. Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nat Biotechnol 2010;28(5):470-7
40. O'Seaghdha CM, Hwang SJ, Larson MG, et al. Analysis of a urinary biomarker panel for incident kidney disease and clinical outcomes. J Am Soc Nephrol 2013;24(11):1880-8
41. Paragas N, Qiu A, Zhang Q, et al. The NGAL reporter mouse detects the response of the kidney to injury in real time. Nat Med 2011;17(2):216-22
42. Borkham-Kamphorst E, Drews F, Weiskirchen R. Induction of lipocalin-2 expression in acute and chronic experimental liver injury moderated by pro-inflammatory cytokines interleukin- 1b through nuclear factor-kB activation. Liver Int 2011;31(5):656-65
43. Flo TH, Smith KD, Sato S, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004;432(7019):917-21
44. Schmidt-Ott KM, Mori K, Li JY, et al. Dual action of neutrophil gelatinaseassociated lipocalin. J Am Soc Nephrol 2007;18(2):407-13
45. Devarajan P. Neutrophil gelatinaseassociated lipocalin (NGAL): a new marker of kidney disease. Scand J Clin Lab Invest Suppl 2008;241:89-94
46. Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinaseassociated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003;14(10):2534-43
47. Kai K, Yamaguchi T, Yoshimatsu Y, et al. Neutrophil gelatinase-associated lipocalin, a sensitive urinary biomarker of acute kidney injury in dogs receiving gentamicin. J Toxicol Sci 2013;38(2):269-77
48. Wasilewska A, Zoch-Zwierz W, Taranta-Janusz K, Michaluk-Skutnik J. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of cyclosporine nephrotoxicity?. Pediatr Nephrol 2010;25(5):889-97
49. Viau A, El Karoui K, Laouari D, et al. Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest 2010;120(11):4065-76
50. Molls RR, Savransky V, Liu M, et al. Keratinocyte-derived chemokine is an early biomarker of ischemic acute kidney injury. Am J Physiol Renal Physiol 2006;290(5):F1187-93
51. Parikh CR, Jani A, Melnikov VY, et al. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis 2004;43(3):405-14
52. Menke J, Iwata Y, Rabacal WA, et al. CSF-1 signals directly to renal tubular epithelial cells to mediate repair in mice. J Clin Invest 2009;119(8):2330-42
53. Isbel NM, Hill PA, Foti R, et al. Tubules are the major site of M-CSF production in experimental kidney disease: correlation with local macrophage proliferation. Kidney Int 2001;60(2):614-25
54. Wada T, Naito T, Griffiths RC, et al. Systemic autoimmune nephritogenic components induce CSF-1 and TNF-a in MRL kidneys. Kidney Int 1997;52(4):934-41
55. Alikhan MA, Jones CV, Williams TM, et al. Colony-stimulating factor-1 promotes kidney growth and repair via alteration of macrophage responses. Am J Pathol 2011;179(3):1243-56
56. Yokoyama H, Kreft B, Kelley VR. Biphasic increase in circulating and renal TNF-a in MRL-lpr mice with differing regulatory mechanisms. Kidney Int 1995;47(1):122-30
57. Vielhauer V, Mayadas TN. Functions of TNF and its receptors in renal disease: distinct roles in inflammatory tissue injury and immune regulation. Semin Nephrol 2007;27(3):286-308
58. Bosomworth MP, Aparicio SR, Hay AW. Urine N-acetyl-b-D-glucosaminidase-a marker of tubular damage?. Nephrol Dial Transplant 1999;14(3):620-6
59. Liangos O, Perianayagam MC, Vaidya VS, et al. Urinary N-acetyl-b- (D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol 2007;18(3):904-12
60. D'Amico G, Bazzi C. Urinary protein and enzyme excretion as markers of tubular damage. Curr Opin Nephrol Hypertens 2003;12(6):639-43
61. Mohammadi-Karakani A, Asgharzadeh-Haghighi S, Ghazi-Khansari M, Hosseini R. Determination of urinary enzymes as a marker of early renal damage in diabetic patients. J Clin Lab Anal 2007;21(6):413-17
62. Westhuyzen J, Endre ZH, Reece G, et al. Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit. Nephrol Dial Transplant 2003;18(3):543-51
63. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136(2):215-33
64. Schena FP, Serino G, Sallustio F. MicroRNAs in kidney diseases: new promising biomarkers for diagnosis and monitoring. Nephrol Dial Transplant 2014;29(4):755-63
65. Zhong X, Chung AC, Chen HY, et al. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol 2011;22(9):1668-81
66. Lan YF, Chen HH, Lai PF, et al. MicroRNA-494 reduces ATF3 expression and promotes AKI. J Am Soc Nephrol 2012;23(12):2012-23
67. Wang G, Kwan BC, Lai FM, et al. Intrarenal expression of miRNAs in patients with hypertensive nephrosclerosis. Am J Hypertens 2010;23(1):78-84
68. Dai Q, Zhao J, Qi X, et al. MicroRNA profiling of rats with ochratoxin A nephrotoxicity. BMC Genomics 2014;15(1):333
69. Bhatt K, Zhou L, Mi QS, et al. MicroRNA-34a is induced via p53 during cisplatin nephrotoxicity and contributes to cell survival. Mol Med 2010;16(9-10):409-16
70. Saikumar J, Hoffmann D, Kim TM, et al. Expression, circulation, and excretion profile of microRNA-21, -155, and -18a following acute kidney injury. Toxicol Sci 2012;129(2):256-67
71. Gallo A, Tandon M, Alevizos I, Illei GG. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One 2012;7(3):e30679
72. Cheng L, Sun X, Scicluna BJ, et al. Characterization and deep sequencing analysis of exosomal and non-exosomal miRNA in human urine. Kidney Int 2014;86(2):433-44
73. Cheng L, Sharples RA, Scicluna BJ, Hill AF. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J Extracell Vesicles 2014;3:doi: 10.3402/jev.v3.23743
74. Pfaller W, Gstraunthaler G. Nephrotoxicity testing in vitro-what we know and what we need to know. Environ Health Perspect 1998;106(Suppl 2):559-69
75. Nielsen R, Birn H, Moestrup SK, et al. Characterization of a kidney proximal tubule cell line, LLC-PK1, expressing endocytotic active megalin. J Am Soc Nephrol 1998;9(10):1767-76
76. Steinmassl D, Pfaller W, Gstraunthaler G, Hoffmann W. LLC-PK1 epithelia as a model for in vitro assessment of proximal tubular nephrotoxicity. In Vitro Cell Dev Biol Anim 1995;31(2):94-106
77. White DJ, Seaman C. LLC-RK1 cell screening test for nephrotoxicity. Methods Mol Biol 1995;43:11-16
78. Fukuishi N, Gemba M. Use of cultured renal epithelial-cells for the study of cisplatin toxicity. Jpn J Pharmacol 1989;50(2):247-9
79. Toutain H, Morin JP. Renal proximal tubule cell cultures for studying druginduced nephrotoxicity and modulation of phenotype expression by medium components. Ren Fail 1992;14(3):371-83
80. Fishman AI, Alexander B, Eshghi M, et al. Nephrotoxin-induced renal cell injury involving biochemical alterations and its prevention with antioxidant. J Clin Med Res 2012;4(2):95-101
81. Ryan MJ, Johnson G, Kirk J, et al. HK- 2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int 1994;45(1):48-57
82. Zhipeng W, Li L, Qibing M, et al. Increased expression of heat shock protein (HSP)72 in a human proximal tubular cell line (HK-2) with gentamicininduced injury. J Toxicol Sci 2006;31(1):61-70
83. Sung MJ, Kim DH, Jung YJ, et al. Genistein protects the kidney from cisplatin-induced injury. Kidney Int 2008;74(12):1538-47
84. Wu Y, Connors D, Barber L, et al. Multiplexed assay panel of cytotoxicity in HK-2 cells for detection of renal proximal tubule injury potential of compounds. Toxicol In Vitro 2009;23(6):1170-8
85. Gunness P, Aleksa K, Kosuge K, et al. Comparison of the novel HK-2 human renal proximal tubular cell line with the standard LLC-PK1 cell line in studying drug-induced nephrotoxicity. Can J Physiol Pharmacol 2010;88(4):448-55
86. Glynne PA. Primary culture of human proximal renal tubular epithelial cells. Methods Mol Med 2000;36:197-205
87. Li W, Lam M, Choy D, et al. Human primary renal cells as a model for toxicity assessment of chemo-therapeutic drugs. Toxicol In Vitro 2006;20(5):669-76
88. Wieser M, Stadler G, Jennings P, et al. hTERT alone immortalizes epithelial cells of renal proximal tubules without changing their functional characteristics. Am J Physiol Renal Physiol 2008;295(5):F1365-75
89. Ellis JK, Athersuch TJ, Cavill R, et al. Metabolic response to low-level toxicant exposure in a novel renal tubule epithelial cell system. Mol Biosyst 2011;7(1):247-57
90. Abraham VC, Taylor DL, Haskins JR. High content screening applied to largescale cell biology. Trends Biotechnol 2004;22(1):15-22
91. Zock JM. Applications of high content screening in life science research. Comb Chem High Throughput Screen 2009;12(9):870-6
92. Bickle M. The beautiful cell: highcontent screening in drug discovery. Anal Bioanal Chem 2010;398(1):219-26
93. Lin Z, Will Y. Evaluation of drugs with specific organ toxicities in organ-specific cell lines. Toxicol Sci 2012;126(1):114-27
94. Johnson AC, Becker K, Zager RA. Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury. Am J Physiol Renal Physiol 2010;299(2):F426-35
95. Sohn SJ, Kim SY, Kim HS, et al. In vitro evaluation of biomarkers for cisplatin-induced nephrotoxicity using HK-2 human kidney epithelial cells. Toxicol Lett 2013;217(3):235-42
96. Keirstead ND, Wagoner MP, Bentley P, et al. Early prediction of polymyxininduced nephrotoxicity with nextgeneration urinary kidney injury biomarkers. Toxicol Sci 2014;137(2):278-91
97. Li Y, Oo ZY, Chang SY, et al. An in vitro method for the prediction of renal proximal tubular toxicity in humans. Toxicol Res 2013;2(5):352-65
98. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotech 2014;32(8):760-72
99. Jang KJ, Suh KY. A multi-layer microfluidic device for efficient culture and analysis of renal tubular cells. Lab Chip 2010;10(1):36-42
100. Jang KJ, Mehr AP, Hamilton GA, et al. Human kidney proximal tubule-on-achip for drug transport and nephrotoxicity assessment. Integr Biol (Camb) 2013;5(9):1119-29
101. Justice BA, Badr NA, Felder RA. 3D cell culture opens new dimensions in cellbased assays. Drug Discov Today 2009;14(1-2):102-7
102. Fisel P, Renner O, Nies AT, et al. Solute carrier transporter and drug-related nephrotoxicity: the impact of proximal tubule cell models for preclinical research. Expert Opin Drug Metab Toxicol 2014;10(3):395-408
103. Astashkina AI, Mann BK, Prestwich GD, Grainger DW. A 3-D organoid kidney culture model engineered for highthroughput nephrotoxicity assays. Biomaterials 2012;33(18):4700-11
104. Astashkina AI, Mann BK, Prestwich GD, Grainger DW. Comparing predictive drug nephrotoxicity biomarkers in kidney 3-D primary organoid culture and immortalized cell lines. Biomaterials 2012;33(18):4712-21
105. DesRochers TM, Suter L, Roth A, Kaplan DL. Bioengineered 3d human kidney tissue, a platform for the determination of nephrotoxicity. PLoS One 2013;8(3):e59219
106. Astashkina A, Grainger DW. Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments. Adv Drug Deliv Rev 2014;69-70:1-18
107. Murphy SV, Atala A. 3D bioprinting of tissues and organs. Nat Biotech 2014;32(8):773-85
108. Priest BT, Bell IM, Garcia ML. Role of hERG potassium channel assays in drug development. Channels 2008;2(2):87-93
109. Tiong HY, Huang P, Xiong S, et al. Drug-induced nephrotoxicity: clinical impact and preclinical in vitro models. Mol Pharm 2014;11(7):1933-48
110. Gomella LG, Haist SA. In: Jim S, Harriet L, editors. Clinician's pocket reference. 11th Edition. McGraw-Hill Medical, New York, USA; 2007
111. Papadakis MA, McPhee SJ, Rabow MW. In: Christine D, Harriet L, Barbara H. Current medical diagnosis & treatment. McGraw-Hill Education, Columbus, OH; 2014
112. Chaturvedi S, Farmer T, Kapke GF. Assay validation for KIM-1: human urinary renal dysfunction biomarker. Int J Biol Sci 2009;5(2):128-34
113. Croda-Todd MT, Soto-Montano XJ, Hernandez-Cancino PA, Juarez-Aguilar E. Adult cystatin C reference intervals determined by nephelometric immunoassay. Clin Biochem 2007;40(13-14):1084-7
114. Weber MH, Scholz P, Stibbe W, Scheler F. Alpha 1-microglobulin in the urine and serum in proteinuria and kidney insufficiency. Klin Wochenschr 1985;63(15):711-17
115. IJ L, Dekker LJ, Koudstaal PJ, et al. Serum clusterin levels are not increased in presymptomatic Alzheimer's disease. J Proteome Res 2011;10(4):2006-10
116. Qu Y, Yang Y, Ma D, Xiao W. Increased trefoil factor 3 levels in the serum of patients with three major histological subtypes of lung cancer. Oncol Rep 2012;27(4):1277-83
117. Bolignano D, Lacquaniti A, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009;4(2):337-44
118. Hata D, Miyazaki M, Seto S, et al. Nephrotic syndrome and aberrant expression of laminin isoforms in glomerular basement membranes for an infant with Herlitz junctional epidermolysis bullosa. Pediatrics 2005;116(4):e601-7
119. Branten AJ, Mulder TP, Peters WH, et al. Urinary excretion of glutathione S transferases alpha and pi in patients with proteinuria: reflection of the site of tubular injury. Nephron 2000;85(2):120-6
120. Gani DK, Lakshmi D, Krishnan R, Emmadi P. Evaluation of C-reactive protein and interleukin-6 in the peripheral blood of patients with chronic periodontitis. J Indian Soc Periodontol 2009;13(2):69-74
121. Sun A, Wang JT, Chia JS, Chiang CP. Serum interleukin-8 level is a more sensitive marker than serum interleukin-6 level in monitoring the disease activity of oral lichen planus. Br J Dermatol 2005;152(6):1187-92
122. Wong CK, Li EK, Ho CY, Lam CW. Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus. Rheumatology 2000;39(10):1078-81
123. Wiener E, Wanachiwanawin W, Chinprasertsuk S, et al. Increased serum levels of macrophage colony-stimulating factor (M-CSF) in alpha- and betathalassaemia syndromes: correlation with anaemia and monocyte activation. Eur J Haematol 1996;57(5):364-9
124. Kapadia SR, Yakoob K, Nader S, et al. Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. J Am Coll Cardiol 2000;36(1):208-12
125. Pelsers MM, Morovat A, Alexander GJ, et al. Liver fatty acid-binding protein as a sensitive serum marker of acute hepatocellular damage in liver transplant recipients. Clin Chem 2002;48(11):2055-7
126. Alhadi HA, Fox KA. Do we need additional markers of myocyte necrosis: the potential value of heart fatty-acid-binding protein. QJM 2004;97(4):187-98
127. Chagan-Yasutan H, Saitoh H, et al. Persistent elevation of plasma osteopontin levels in HIV patients despite highly active antiretroviral therapy. Tohoku J Exp Med 2009;218(4):285-92
128. Racusen LC, Monteil C, Sgrignoli A, et al. Cell lines with extended in vitro growth potential from human renal proximal tubule: Characterization, response to inducers, and comparison with established cell lines. J Lab Clin Med 1997;129(3):318-29
129. Morin JP, Marouillat S, Lendormi C, Monteil C. Comparative impact of cephaloridine on glutathione and related enzymes in LLC-PK1, LLC-RK1, and primary cultures of rat and rabbit proximal tubule cells. Cell Biol Toxicol 1996;12(4-6):275-82
130. Monteil C, Marouillat S, Elkaz V, et al. Phenotypic characterization of the rabbit kidney cell line LLC-RK1 implication for pharmacotoxicological studies. Cell Biol Toxicol 1996;12(4-6):378-8
131. Prozialeck WC, Edwards JR, Lamar PC, Smith CS. Epithelial barrier characteristics and expression of cell adhesion molecules in proximal tubulederived cell lines commonly used for in vitro toxicity studies. Toxicol In Vitro 2006;20(6):942-53
132. Chu JJ, Ng ML. Infection of polarized epithelial cells with flavivirus West Nile: polarized entry and egress of virus occur through the apical surface. J Gen Virol 2002;83(Pt 10):2427-35
133. McClane BA, Chakrabarti G. New insights into the cytotoxic mechanisms of Clostridium perfringens enterotoxin. Anaerobe 2004;10(2):107-14
134. Carranza-Rosales P, Said-Fernandez S, Sepulveda-Saavedra J, et al. Morphologic and functional alterations induced by low doses of mercuric chloride in the kidney OK cell line: ultrastructural evidence for an apoptotic mechanism of damage. Toxicology 2005;210(2-3):111-21
135. McNeil E, Capaldo CT, Macara IG. Zonula occludens-1 function in the assembly of tight junctions in Madin- Darby canine kidney epithelial cells. Mol Biol Cell 2006;17(4):1922-32
136. Hayashi K. Role of tight junctions of polarized epithelial MDCK cells in the replication of herpes simplex virus type 1. J Med Virol 1995;47(4):323-9
137. Schiwek D, Endlich N, Holzman L, et al. Stable expression of nephrin and localization to cell-cell contacts in novel murine podocyte cell lines. Kidney Int 2004;66(1):91-101
138. Jenkinson SE, Chung GW, van Loon E, et al. The limitations of renal epithelial cell line HK-2 as a model of drug transporter expression and function in the proximal tubule. Pflugers Arch 2012;464(6):601-11
139. Prozialeck WC, Edwards JR. Cell adhesion molecules in chemically-induced renal injury. Pharmacol Ther 2007;114(1):74-93